▲ bullish
Impact
PhaseApproved
Time to marketAlready approved and commercialized (since January 2022). Label expansion into cutaneous melanoma depends on Phase 3 TEBE-AM data expected by end of 2026; if positive, an sBLA submission would follow, with potential approval in 2027-2028.
KIMMTRAK tebentafusp Updated Sep 4
What to watch
The key near-term catalyst is the Phase 3 TEBE-AM topline readout for KIMMTRAK in cutaneous melanoma, expected by end of 2026 (~4 months away). A positive result could double the addressable market; a negative readout would be a major setback. With ~16.4% of shares short and ~18.8 days to cover, a positive readout could trigger significant short-covering upside. Watch for enrollment completion announcements and any data updates at medical meetings in H2 2026.
Bull case
- KIMMTRAK is the first and only FDA-approved T cell engager (ImmTAC) for a solid tumor, approved for metastatic uveal melanoma in January 2022, a rare cancer with no prior approved therapies.
- Five-year overall survival data from the Phase 3 trial showed KIMMTRAK doubled survival rates (16% vs 8% in control arm), the longest follow-up for any T cell engager in a solid tumor.
- Revenue is growing: FY2025 net sales of $400M (+29% YoY), Q2 2026 revenue of $115.9M (+18% YoY), with $880M cash providing deep runway.
Bear case
- KIMMTRAK is Immunocore's sole revenue source, any sales disruption, pricing pressure, or competitive threat would directly hit financials (Q2 2026 8-K shows net loss of $0.8M).
- Revenue growth is decelerating: FY2025 grew 29% YoY to $400M, but Q2 2026 grew only 18% YoY to $115.9M, and management expects moderating growth in 2026.
- The TEBE-AM Phase 3 trial in cutaneous melanoma is a binary risk, if it fails, the stock could drop sharply given the high short interest and single-product concentration.